Probiotix Health PLC - New commercialisation partner in Asia Pacific

ProBiotix Health plc

("ProBiotix" or the "Company")

New commercialisation partner in Asia Pacific

ProBiotix Health plc (AQSE: PBX), a life sciences company developing clinically proven probiotic solutions to tackle chronic lifestyle diseases like high cholesterol, high blood pressure and atherosclerosis, announces the appointment of Nutraconnect Pte Ltd ("Nutraconnect") to develop and implement go-to-market strategies for LP_LDL® as an ingredient, and CholBiome® products, in the Asia Pacific ("APAC") region.

Nutraconnect is a nutraceutical business growth acceleration service headquartered in Singapore. The company provides end-to-end solutions for global nutraceutical companies that are looking to establish a foundation for sustainable growth in the fragmented, but vibrant APAC market. Nutraconnect possesses an established network of industry contacts and a wealth of experience in successfully bringing innovative and science backed ingredients and products to markets in the region.

Stephen O'Hara, CEO of ProBiotix Health plc, commented: "Nutraconnect brings extensive industry expertise and a network of high-level contacts in the APAC region, combined with an extensive distribution and agency network. This agreement will help expedite the commercialisation of LP_LDL® and CholBiome® in important countries in the region, whilst allowing ProBiotix to focus internal resources on developing new opportunities in dairy and building a presence in the North American market."

For further information, please contact:

About ProBiotix - www.probiotixhealth-ir.com

ProBiotix Health was established by OptiBiotix Health Plc to develop probiotics to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. Since its creation, ProBiotix has become a global leader in microbiome modulating probiotics for use in functional foods, supplements and biotherapeutics.

Independent clinical studies have shown that ProBiotix's principal product, LP_LDL®, which is protected by an extensive patent portfolio, can reduce key cardiovascular risk biomarkers: Total Cholesterol of up to 34.6%, LDL-Cholesterol by 28.4%, and apoB (biomarker of atheroschlerosis) by 28.6%. Since launching its CholBiome® products containing LP_LDL® in May 2017, ProBiotix has signed over 41 agreements and its products are now commercialised in 60 countries.

LP_LDL® was designated Generally Recognized As Safe ("GRAS") by an independent Expert GRAS Panel in the United States in February 2019, which extends its applications from use as a supplement to use as a functional ingredient in a wide range of food, dairy, and beverage products in the USA.